Black Seed for Blood Sugar
Black seed (Nigella sativa) — also called black cumin or kalonji — has quietly accumulated more human trial evidence for glycemic control than most of the herbs above it in reputation. The trials are small and the preparations are not standardised, but there are a lot of them and they point the same way.
Evidence tier 2, at the strong end. Consistent pooled effects from many small studies of modest quality.
Table of Contents
What the Pooled Evidence Shows
Karimi and colleagues' 2025 systematic review and meta-analysis in Complementary Therapies in Medicine pooled 16 randomised controlled trials in type 2 diabetes and found black seed supplementation significantly reduced:
- Fasting blood glucose by 21.43 mg/dL (P = 0.005)
- HbA1c by 0.44 percentage points (P = 0.01)
- Total cholesterol by 18.80 mg/dL (P = 0.04), with LDL also reduced
Separately, Jafari and colleagues published a GRADE-assessed umbrella review in Pharmacological Research in 2025 covering 82 studies and 5,026 participants, with doses ranging from 200 to 4,600 mg/day over 1 to 48 weeks — a genuinely large body of work by herbal-supplement standards.
An HbA1c reduction of 0.44 points is not trivial; it is in the range some pharmaceutical add-ons achieve. The caveats are the familiar ones and they are real: individual trials are small, blinding is variable, much of the work comes from a small number of research environments, and — the practical problem — "black seed" covers whole seed, ground seed, fixed oil and thymoquinone-standardised extracts, which are not interchangeable.
Thymoquinone
Thymoquinone is the principal active constituent and the one most preparations are standardised against when they are standardised at all. The proposed actions are the usual cluster — improved insulin sensitivity, protection of pancreatic beta cells from oxidative stress, reduced hepatic gluconeogenesis — supported mainly by preclinical work.
The non-standardisation is the crux for anyone buying it. A trial using a thymoquinone-standardised oil and a jar of ground kalonji from a grocery are not the same intervention, and the meta-analytic average is computed across both.
Dosing
Trial doses span 200 mg to 4,600 mg a day — a twenty-threefold range, which is itself a statement about how unsettled the dosing is. The commonly used practical range is around 1–3 g/day of ground seed, or 1–2 g/day of the oil, taken with food.
Because the preparations differ so much, the sensible approach is to pick one product, use it consistently, and measure — rather than to trust that any two black seed products do the same thing.
Cautions
- It lowers blood glucose, and so does your medication. The effects add. With insulin or a sulfonylurea this is a hypoglycemia risk, and dose changes belong with the prescriber — see hypoglycemia awareness and prevention.
- Possible effects on drug metabolism. Thymoquinone has shown CYP-modulating activity in preclinical work; be cautious with narrow-therapeutic-index medications.
- Avoid therapeutic doses in pregnancy — uterine effects are reported in animal studies.
- Measure, do not assume. Adding a supplement without measuring means you learn about an interaction from a symptom rather than from a number.
Key Research Papers
Every DOI below was checked against Crossref and the abstract read for support before it was listed.
- Karimi, et al. Effects of black seed (Nigella sativa L.) on cardiometabolic indices in type 2 diabetic patients: a systematic review and meta-analysis. Complementary Therapies in Medicine, 2025;90:103174. Sixteen randomised trials.
- Jafari, et al. Does Nigella sativa supplementation improve cardiovascular disease risk factors? A comprehensive GRADE-assessed systematic review. Pharmacological Research, 2025;219:107882. Eighty-two studies, 5,026 participants.